Advertisement

Effects of Alpha Lipoic Acid on Multiple Cytokines and Biomarkers and Recurrence of Atrial Fibrillation Within 1 Year of Catheter Ablation

Published:February 10, 2017DOI:https://doi.org/10.1016/j.amjcard.2017.01.040
      Catheter ablation (CA) is a procedure commonly used to restore sinus rhythm in patients with atrial fibrillation (AF). However, AF recurrence after CA remains a relevant clinical issue. We tested the effects of an oral antioxidant treatment (alpha lipoic acid [ALA]) on AF recurrence post-CA. Patients with paroxysmal AF have been enrolled in a randomized, prospective, double-blind, controlled placebo trial. After CA, patients have been randomly assigned to receive ALA oral supplementation (ALA group) or placebo (control group) and evaluated at baseline and after a 12-month follow-up: 73 patients completed the 12-month follow-up (ALA: 33 and control: 40). No significant difference has been detected between the 2 groups at baseline. Strikingly, 1 year after CA, ALA therapy significantly reduced serum markers of inflammation. However, there was no significant difference in AF recurrence events at follow-up comparing ALA with placebo group. Multivariate analysis revealed that the only independent prognostic risk factor for AF recurrence after CA is age. In conclusion, ALA therapy reduces serum levels of common markers of inflammation in ablated patients. Nevertheless, ALA does not prevent AF recurrence after an ablative treatment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chugh S.S.
        • Havmoeller R.
        • Narayanan K.
        • Singh D.
        • Rienstra M.
        • Benjamin E.J.
        • Gillum R.F.
        • Kim Y.H.
        • McAnulty Jr., J.H.
        • Zheng Z.J.
        • Forouzanfar M.H.
        • Naghavi M.
        • Mensah G.A.
        • Ezzati M.
        • Murray C.J.
        Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.
        Circulation. 2014; 129: 837-847
        • Marfella R.
        • Sasso F.C.
        • Siniscalchi M.
        • Cirillo M.
        • Paolisso P.
        • Sardu C.
        • Barbieri M.
        • Rizzo M.R.
        • Mauro C.
        • Paolisso G.
        Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients.
        J Am Coll Cardiol. 2013; 62: 525-530
        • Santulli G.
        • Iaccarino G.
        • De Luca N.
        • Trimarco B.
        • Condorelli G.
        Atrial fibrillation and microRNAs.
        Front Physiol. 2014; 5: 15
        • January C.T.
        • Wann L.S.
        • Alpert J.S.
        • Calkins H.
        • Cigarroa J.E.
        • Cleveland Jr., J.C.
        • Conti J.B.
        • Ellinor P.T.
        • Ezekowitz M.D.
        • Field M.E.
        • Murray K.T.
        • Sacco R.L.
        • Stevenson W.G.
        • Tchou P.J.
        • Tracy C.M.
        • Yancy C.W.
        • American College of Cardiology/American Heart Association Task Force on Practice Guidelines
        2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
        J Am Coll Cardiol. 2014; 64: e1-e76
        • Kirchhof P.
        • Benussi S.
        • Kotecha D.
        • Ahlsson A.
        • Atar D.
        • Casadei B.
        • Castella M.
        • Diener H.C.
        • Heidbuchel H.
        • Hendriks J.
        • Hindricks G.
        • Manolis A.S.
        • Oldgren J.
        • Popescu B.A.
        • Schotten U.
        • Van Putte B.
        • Vardas P.
        • Authors/Task Force Members, Document Reviewers
        2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European heart rhythm association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO).
        Eur Heart J. 2016; 50: e1-e88
        • Calkins H.
        • Reynolds M.R.
        • Spector P.
        • Sondhi M.
        • Xu Y.
        • Martin A.
        • Williams C.J.
        • Sledge I.
        Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses.
        Circ Arrhythm Electrophysiol. 2009; 2: 349-361
        • Issac T.T.
        • Dokainish H.
        • Lakkis N.M.
        Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data.
        J Am Coll Cardiol. 2007; 50: 2021-2028
        • Boos C.J.
        • Anderson R.A.
        • Lip G.Y.
        Is atrial fibrillation an inflammatory disorder?.
        Eur Heart J. 2006; 27: 136-149
        • Engelmann M.D.
        • Svendsen J.H.
        Inflammation in the genesis and perpetuation of atrial fibrillation.
        Eur Heart J. 2005; 26: 2083-2092
        • Kostapanos M.S.
        • Liberopoulos E.N.
        • Goudevenos J.A.
        • Mikhailidis D.P.
        • Elisaf M.S.
        Do statins have an antiarrhythmic activity?.
        Cardiovasc Res. 2007; 75: 10-20
        • Gambardella J.
        • Santulli G.
        Integrating diet and inflammation to calculate cardiovascular risk.
        Atherosclerosis. 2016; 253: 258-261
        • Xie W.
        • Santulli G.
        • Reiken S.R.
        • Yuan Q.
        • Osborne B.W.
        • Chen B.X.
        • Marks A.R.
        Mitochondrial oxidative stress promotes atrial fibrillation.
        Scientific Rep. 2015; 5: 11427
        • Wakili R.
        • Voigt N.
        • Kaab S.
        • Dobrev D.
        • Nattel S.
        Recent advances in the molecular pathophysiology of atrial fibrillation.
        J Clin Invest. 2011; 121: 2955-2968
        • Gomes M.B.
        • Negrato C.A.
        Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases.
        Diabetol Metab Syndr. 2014; 6: 80
        • Koufaki M.
        Therapeutic applications of lipoic acid: a patent review (2011-2014).
        Expert Opin Ther Pat. 2014; 24: 993-1005
        • Israel C.W.
        • Gronefeld G.
        • Ehrlich J.R.
        • Li Y.G.
        • Hohnloser S.H.
        Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care.
        J Am Coll Cardiol. 2004; 43: 47-52
        • Koyama T.
        • Sekiguchi Y.
        • Tada H.
        • Arimoto T.
        • Yamasaki H.
        • Kuroki K.
        • Machino T.
        • Tajiri K.
        • Zhu X.D.
        • Kanemoto M.
        • Sugiyasu A.
        • Kuga K.
        • Aonuma K.
        Comparison of characteristics and significance of immediate versus early versus no recurrence of atrial fibrillation after catheter ablation.
        Am J Cardiol. 2009; 103: 1249-1254
        • Kusayama T.
        • Furusho H.
        • Kashiwagi H.
        • Kato T.
        • Murai H.
        • Usui S.
        • Kaneko S.
        • Takamura M.
        Inflammation of left atrial epicardial adipose tissue is associated with paroxysmal atrial fibrillation.
        J Cardiol. 2016; 68: 406-411
        • Koyama T.
        • Tada H.
        • Sekiguchi Y.
        • Arimoto T.
        • Yamasaki H.
        • Kuroki K.
        • Machino T.
        • Tajiri K.
        • Zhu X.D.
        • Kanemoto-Igarashi M.
        • Sugiyasu A.
        • Kuga K.
        • Nakata Y.
        • Aonuma K.
        Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial.
        J Am Coll Cardiol. 2010; 56: 1463-1472
        • Sardu C.
        • Carreras G.
        • Katsanos S.
        • Kamperidis V.
        • Pace M.C.
        • Passavanti M.B.
        • Fava I.
        • Paolisso P.
        • Pieretti G.
        • Nicoletti G.F.
        • Santulli G.
        • Paolisso G.
        • Marfella R.
        Metabolic syndrome is associated with a poor outcome in patients affected by outflow tract premature ventricular contractions treated by catheter ablation.
        BMC Cardiovasc Disord. 2014; 14: 176
        • Tankova T.
        • Cherninkova S.
        • Koev D.
        Treatment for diabetic mononeuropathy with alpha-lipoic acid.
        Int J Clin Pract. 2005; 59: 645-650
        • Golbidi S.
        • Badran M.
        • Laher I.
        Diabetes and alpha lipoic Acid.
        Front Pharmacol. 2011; 2: 69
        • Bas H.A.
        • Aksoy F.
        • Icli A.
        • Varol E.
        • Dogan A.
        • Erdogan D.
        • Ersoy I.
        • Arslan A.
        • Ari H.
        • Bas N.
        • Sutcu R.
        • Ozaydin M.
        The association of plasma oxidative status and inflammation with the development of atrial fibrillation in patients presenting with ST elevation myocardial infarction.
        Scand J Clin Lab Invest. 2017; 77: 77-82
        • Youn J.Y.
        • Zhang J.
        • Zhang Y.
        • Chen H.
        • Liu D.
        • Ping P.
        • Weiss J.N.
        • Cai H.
        Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase.
        J Mol Cell Cardiol. 2013; 62: 72-79
        • D'Ascia S.L.
        • D'Ascia C.
        • Marino V.
        • Lombardi A.
        • Santulli R.
        • Chiariello M.
        • Santulli G.
        Cardiac resynchronisation therapy response predicts occurrence of atrial fibrillation in non-ischaemic dilated cardiomyopathy.
        Int J Clin Pract. 2011; 65: 1149-1155
        • Drolet B.
        • Simard C.
        • Gailis L.
        • Daleau P.
        Ischemic, genetic and pharmacological origins of cardiac arrhythmias: the contribution of the Quebec Heart Institute.
        Can J Cardiol. 2007; 23 Suppl B: 15B-22B
        • Jeong E.M.
        • Liu M.
        • Sturdy M.
        • Gao G.
        • Varghese S.T.
        • Sovari A.A.
        • Dudley Jr., S.C.
        Metabolic stress, reactive oxygen species, and arrhythmia.
        J Mol Cell Cardiol. 2012; 52: 454-463
        • Dong M.
        • Ren J.
        What fans the fire: insights into mechanisms of leptin in metabolic syndrome-associated heart diseases.
        Curr Pharm Des. 2014; 20: 652-658
        • Santulli G.
        • D'Ascia S.L.
        • D'Ascia C.
        Development of atrial fibrillation in recipients of cardiac resynchronization therapy: the role of atrial reverse remodelling.
        Can J Cardiol. 2012; 28 (author reply 245 e217–248): 245 e217
        • Catanzaro J.N.
        • Calkins H.
        An approach to catheter ablation of atrial fibrillation in the elderly.
        Card Electrophysiol Clin. 2012; 4: 119-125